Cel-Sci (NYSEAMERICAN:CVM) Releases Earnings Results

Cel-Sci (NYSEAMERICAN:CVM) announced its earnings results on Friday. The company reported ($0.47) earnings per share (EPS) for the quarter, FiscalAI reports.

Cel-Sci Price Performance

CVM traded up $0.05 during trading on Friday, reaching $1.54. The stock had a trading volume of 217,281 shares, compared to its average volume of 236,230. Cel-Sci has a 1-year low of $0.89 and a 1-year high of $13.48. The stock has a 50 day moving average of $1.23 and a two-hundred day moving average of $2.71. The company has a quick ratio of 0.54, a current ratio of 0.60 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $26.92 million, a price-to-earnings ratio of -0.16 and a beta of 0.63.

Institutional Trading of Cel-Sci

A number of institutional investors and hedge funds have recently modified their holdings of the company. HighTower Advisors LLC acquired a new position in Cel-Sci in the 4th quarter valued at $53,000. HRT Financial LP bought a new position in shares of Cel-Sci in the fourth quarter worth about $60,000. XTX Topco Ltd acquired a new position in shares of Cel-Sci during the 4th quarter worth about $66,000. US Bancorp DE acquired a new stake in Cel-Sci in the 3rd quarter valued at approximately $80,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Cel-Sci during the fourth quarter worth approximately $81,000. 12.08% of the stock is currently owned by institutional investors and hedge funds.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.